SEC Form 4 · accession 0001209191-16-135934
Adamas Pharmaceuticals Inc · ADMS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John A MacPhee
Director
Period of report
Aug 5, 2016
Accepted (ET)
Aug 8, 2016 · 5:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001328143
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $13.68 | Aug 5, 2016 | A | 12,600 | A | — | Aug 4, 2026 | Common Stock | 12,600 | 12,600 | D |
Explanation of responses
- F1The Option shares shall vest as follows: 100% of the option shares shall vest on the date 1 year from August 5, 2016, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of each such date.